|
CSF1R |
colony stimulating factor 1 receptor |
- Other interleukin signaling
- Transcriptional Regulation by VENTX
|
- Imatinib
- Sunitinib
- ABT-869
- 5-CYANO-FURAN-2-CARBOXYLIC ACID [5-HYDROXYMETHYL-2-(4-METHYL-PIPERIDIN-1-YL)-PHENYL]-AMIDE
- 6-CHLORO-3-(3-METHYLISOXAZOL-5-YL)-4-PHENYLQUINOLIN-2(1H)-ONE
- Fostamatinib
- Erdafitinib
- Pexidartinib
|
|
|
DDX5 |
DEAD-box helicase 5 |
- SUMOylation of transcription cofactors
- mRNA Splicing - Major Pathway
- Estrogen-dependent gene expression
- Replication of the SARS-CoV-1 genome
- Replication of the SARS-CoV-2 genome
|
|
|
|
FANCC |
FA complementation group C |
- Fanconi Anemia Pathway
- TP53 Regulates Transcription of DNA Repair Genes
|
|
|
|
FASLG |
Fas ligand |
- Caspase activation via Death Receptors in the presence of ligand
- Regulation by c-FLIP
- RIPK1-mediated regulated necrosis
- CASP8 activity is inhibited
- Interleukin-4 and Interleukin-13 signaling
- Dimerization of procaspase-8
- FasL/ CD95L signaling
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
- FOXO-mediated transcription of cell death genes
- TNFs bind their physiological receptors
|
|
- Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
|
|
FTL |
ferritin light chain |
- Scavenging by Class A Receptors
- Golgi Associated Vesicle Biogenesis
- Neutrophil degranulation
- Iron uptake and transport
|
- Iron Dextran
- Protoporphyrin
- Ferric pyrophosphate
- Sodium ferric gluconate complex
- Ferric pyrophosphate citrate
|
- Neurodegeneration with brain iron accumulation (NBIA); Hallervorden-Spatz syndrome; Neuroferritinopathy; Aceruloplasminemia
|
|
GLIS2 |
GLIS family zinc finger 2 |
|
|
- Nephronophthisis-medullary cystic kidney disease, including; Nephronophthisis (NPH) ; Nephronophthisis-like nephropathy 1; Medullary cystic kidney disease 1; Medullary cystic kidney disease 2 (MSKD2)
|
|
LCK |
LCK proto-oncogene, Src family tyrosine kinase |
- GPVI-mediated activation cascade
- PIP3 activates AKT signaling
- Signaling by SCF-KIT
- Signaling by SCF-KIT
- Regulation of KIT signaling
- Nef and signal transduction
- Nef Mediated CD4 Down-regulation
- Downstream TCR signaling
- Phosphorylation of CD3 and TCR zeta chains
- Translocation of ZAP-70 to Immunological synapse
- Generation of second messenger molecules
- PECAM1 interactions
- Constitutive Signaling by Aberrant PI3K in Cancer
- DAP12 signaling
- DAP12 signaling
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- CD28 dependent Vav1 pathway
- CTLA4 inhibitory signaling
- PD-1 signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Interleukin-2 signaling
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- FLT3 signaling through SRC family kinases
|
- Dasatinib
- AP-22408
- Staurosporine
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- {4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid
- Phosphoaminophosphonic Acid-Adenylate Ester
- 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
- 2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE
- 5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE
- N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
- N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
- N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine
- Ponatinib
- Nintedanib
- Fostamatinib
- Zanubrutinib
|
- Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
|
|
MAP2K1 |
mitogen-activated protein kinase kinase 1 |
- MAPK3 (ERK1) activation
- Frs2-mediated activation
- Signal transduction by L1
- Uptake and function of anthrax toxins
- RAF activation
- MAP2K and MAPK activation
- Negative feedback regulation of MAPK pathway
- MAP3K8 (TPL2)-dependent MAPK1/3 activation
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Signaling downstream of RAS mutants
- Signaling by MAP2K mutants
- Signaling by RAF1 mutants
|
- K-252a
- 5-Bromo-N-[(2S)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
- Cobimetinib
- Bosutinib
- (5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide
- 2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide
- PD-0325901
- N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine
- 2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE
- Trametinib
- Selumetinib
|
- Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
|
|
PDGFRA |
platelet derived growth factor receptor alpha |
- PIP3 activates AKT signaling
- Downstream signal transduction
- Signaling by PDGF
- Constitutive Signaling by Aberrant PI3K in Cancer
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Imatinib-resistant PDGFR mutants
- Sunitinib-resistant PDGFR mutants
- Regorafenib-resistant PDGFR mutants
- Sorafenib-resistant PDGFR mutants
- PDGFR mutants bind TKIs
|
- Becaplermin
- Imatinib
- Sunitinib
- XL820
- Olaratumab
- Pazopanib
- Midostaurin
- Regorafenib
- Ponatinib
- Lenvatinib
- Nintedanib
- Foreskin keratinocyte (neonatal)
- Fostamatinib
- Erdafitinib
- Amuvatinib
- Ripretinib
|
|
|
PDGFRB |
platelet derived growth factor receptor beta |
- PIP3 activates AKT signaling
- Downstream signal transduction
- Signaling by PDGF
- Constitutive Signaling by Aberrant PI3K in Cancer
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
|
- Becaplermin
- Sorafenib
- Imatinib
- Dasatinib
- Sunitinib
- XL999
- XL820
- Pazopanib
- Midostaurin
- Regorafenib
- Nintedanib
- Polaprezinc
- Trapidil
- Foreskin fibroblast (neonatal)
- Fostamatinib
- Erdafitinib
- Pexidartinib
- Ripretinib
- Pralsetinib
|
|
|
SMAD2 |
SMAD family member 2 |
- Signaling by NODAL
- Signaling by NODAL
- Signaling by Activin
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- SMAD4 MH2 Domain Mutants in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGFBR1 KD Mutants in Cancer
- Transcriptional regulation of pluripotent stem cells
- Ub-specific processing proteases
- FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
- FOXO-mediated transcription of cell cycle genes
- FOXO-mediated transcription of cell cycle genes
|
|
|
|
SQSTM1 |
sequestosome 1 |
- NRIF signals cell death from the nucleus
- p75NTR recruits signalling complexes
- NF-kB is activated and signals survival
- PINK1-PRKN Mediated Mitophagy
- Interleukin-1 signaling
- Pexophagy
|
|
- Paget's disease of bone and related disorders, including: ; Paget's disease of bone (PDB); Familial expansile osteolysis (FEO); Early-onset Paget's disease of bone (PDB2); Expansile skeletal hyperphosphatasia (ESH); Juvenile Paget's disease (JPD)
|
|
UMPS |
uridine monophosphate synthetase |
|
- 6-hydroxyuridine-5'-phosphate
|
|
|
ADAP1 |
ArfGAP with dual PH domains 1 |
- Nuclear signaling by ERBB4
|
|
|
|
AMBP |
alpha-1-microglobulin/bikunin precursor |
- Scavenging of heme from plasma
|
|
|
|
APLP2 |
amyloid beta precursor like protein 2 |
- Platelet degranulation
- Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
- Post-translational protein phosphorylation
|
- Zinc
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
|
|
APPL1 |
adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 |
- Caspase activation via Dependence Receptors in the absence of ligand
|
|
|
|
ATP5IF1 |
ATP synthase inhibitory factor subunit 1 |
|
|
|
|
BEX1 |
brain expressed X-linked 1 |
|
|
|
|
BEX2 |
brain expressed X-linked 2 |
|
|
|